Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergies
Alcon's PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
May 2nd, 2008
Alcon, Inc. (NYSE:ACL) announced that the U.S. Food and Drug Administration (FDA) has approved PATANASE(R) (olopatadine hydrochloride) nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older. PATANASE(R) nasal spray, an extension to Alcon's market-leading ocular allergy product line, will be available in May of this year. "We look forward to providing doctors the opportunity to prescribe PATANASE(R) to their patients who need and want a fast-acting nasal spray that quickly relieves symptoms," said Kevin Buehler, Alcon's senior vice president, global markets and chief marketing officer. "We are excited to enter the...
Source: Health Business Week (2008-05-02)
|
